Introduction
A growing number of diseases, such as cancer, chronic inflammation and diabetic retinopathy, are characterized by excess angiogenesis. Progression of these diseases may depend on the attraction of blood vessels to oxygenate and nurture the growing tissue. Among the tumor-derived growth factors, vascular endothelial growth factor (VEGF)-A is a key angiogenic factor most frequently used by tumors and other tissues to switch on their angiogenic phenotypes (Eriksson and Alitalo, 1999) . The angiogenic signals triggered by members of the VEGF family are mainly mediated by the activation of two homologous tyrosine kinase receptors, VEGF receptor, VEGFR-1 and VEGFR-2, both of which are expressed on blood vessel endothelial cells (Mustonen and Alitalo, 1995) . VEGF-A binds to VEGFR1 and VEGFR2, and induces vasculogenesis, angiogenesis and vascular permeability.
Endothelial adherens junctions are adhesive intercellular contacts that are crucial for the maintenance and regulation of normal microvascular function (Dejana et al., 1995) . Alterations in adherens junction assembly influence endothelial cell motility, vascular morphogenesis and permeability. Moreover, recent studies indicate that components of adherens junctions also participate to intracellular signaling, suggesting that these complexes are plasma membrane domains integrating chemical and mechanical signaling information (Corada et al., 1999) . The major cell-cell adhesion molecule at endothelial adherens junctions is VEcadherin, a cadherin family member specifically expressed in endothelial cells Corada et al., 1999) . The inactivation of the corresponding gene induced an early lethal phenotype in the mouse. VE-cadherinÀ/À endothelial cells were still able to form the primitive vascular plexus, but vascular remodelling was missing, suggesting the importance of VE-cadherin in angiogenesis during early development (Vittet et al., 1997; Gory-Faure et al., 1999) . In adult, the adhesive properties of VE-cadherin are crucial to maintain endothelial cells adherent to one another . In addition to its role in cell-cell adhesion, VE-cadherin was shown to be required for transduction of the VEGF survival pathway (Carmeliet et al., 1999) . The cytoplasmic domain of VE-cadherin comprises the juxtamembrane domain that binds to the p120 catenin, a protein of the armadillo family, and the carboxylterminal domain that interacts with b-catenin or plakoglobin . This cytoplasmic domain of VE-cadherin was shown to regulate endothelial protrusive activity in vitro, suggesting that this domain may play a prominent part in invasive processes (Kouklis et al., 2003) .
Tyrosine phosphorylation of the cadherin-catenin complex has been proposed as a mechanism that regulates the stability of cell-cell junctions. Interestingly, the cytoplasmic domain of VE-cadherin contains nine tyrosine that represent potential target sites for tyrosine kinases. Indeed, VE-cadherin tyrosine phosphorylation has been reported in endothelial cells under several conditions including stimulation by VEGF Zhao and Davis, 1998; Shasby et al., 2002; Su et al., 2002) . We recently reported that plateletactivating factor (PAF) increased VE-cadherin tyrosine phosphorylation in mouse endothelial cells and its association with the phosphatidylinositol 3 0 -(PtdIns3 0 )-kinase (Hudry-Clergeon et al., 2005) . This covalent modification was correlated with PAF induced cell-cell disruption possibly through alteration in adherens junction composition. Furthermore, we showed that VE-cadherin was tyrosine phosphorylated in vivo in mice in ovaries and uterus subjected to hormonal induction, in correlation with the angiogenic switch observed in these tissues. Importantly, VE-cadherin tyrosine phosphorylation was weak or undetectable in endothelial cells from resting tissues (Lambeng et al., 2005) . Therefore, modulation of the tyrosine phosphorylation status of VE cadherin would be critical for regulating angiogenesis, and permeability (Wallez et al., 2006) .
The cytoplasmic tyrosine kinases of the Src family play important roles in mitogenic responses induced by growth factor. Src kinase has been found both overexpressed and highly activated in a number of human cancers, and may play an important role in the acquisition of the invasive and metastatic phenotype (Cartwright et al., 1990 (Cartwright et al., , 1994 Talamonti et al., 1993; Verbeek et al., 1996; Lutz et al., 1998; van Oijen et al., 1998) . Upon activation, Src kinase phosphorylated multiple substrates, including paxillin (Turner, 1990) , p130cas (Nakamoto et al., 1996) and focal adhesion kinase (FAK) (Calalb et al., 1995) , and is required for cell adhesion (Verbeek et al., 1996) , cell spreading (Kaplan et al., 1995) and turnover of focal adhesions (Fincham and Frame, 1998) . More recently, evidence showing an important role of Src kinase in the activation of angiogenesis, especially in regulating vascular permeability, has emerged (Eliceiri et al., 1999) . In addition, the presence of Src family tyrosine kinases in cadherin-containing adherens junctions has been reported (Tsukita et al., 1991) . Importantly, we found an in vivo association of VE-cadherin with Src kinase in mouse tissues (Lambeng et al., 2005) . Moreover, the role for Src in angiogenesis has been shown using the resveratrol, which impaired VEGF-induced endothelial cells tube formation and VE-cadherin tyrosine phosphorylation (Lin et al., 2003) . Altogether, these reports from the literature suggest a potential regulation of VE-cadherin by Src kinase. Two recent reports of the literature have identified several VEcadherin tyrosine phosphorylation sites in several conditions. Baumeister et al. (2005) reported that C-terminal Src kinase (Csk) could interact with VE-cadherin once phosphorylated on Y685. In contrast, upon tyrosine phosphatases inhibitors treatment, other sites were found to be phosphorylated in the VE-cadherin from human umbilical vein endothelial cells (HUVECs) (Potter et al., 2005) . Thus, actually the identity of the phosphorylation sites in human VE-cadherin as well as the kinases operating this phosphorylation remains elusive.
Two goals prompted the present work. One was to examine whether VE-cadherin was a direct substrate for Src kinase and the other was to identify the phosphorylated site(s) in vitro by Src kinase and in endothelial cells in response to VEGF stimulation. Our data clearly showed that Src kinase was responsible for VE-cadherin tyrosine phosphorylation in response to VEGF and that Y685 was the specific site for Src kinase in the VEcadherin cytoplasmic domain. Moreover, we show that this process appears to be critical for VEGF-induced endothelial cell migration.
Results

Tyrosine phosphorylation of VE-cadherin is induced by active Src in CHO cells
We reasoned that VE-cadherin could be a direct substrate of Src for two reasons: (i) Src is associated with VE-cadherin in vivo and in vitro; and (ii) VEGFinduced VE-cadherin tyrosine phosphorylation is Srcdependent.
To explore this possibility, we used VE-cadherintransfected Chinese hamster ovary cells (CHO) cells (Figure 1a ) that were transiently transfected either with constitutively active Src (Y530F), with kinase-dead Src (K298M) or with the empty vector. Immunoblotting of untransfected cells with the anti-Src antibody showed the presence of Src kinase in CHO cells. Transfection of Src kinase resulted in increased total Src expression (Figure 1b, below) .
The VE-cadherin tyrosine phosphorylation levels were analysed by immunoprecipitation and immunoblotting with an anti-P-tyr antibody. The tyrosinephosphorylated form of the human VE-cadherin was detected in cells transfected with constitutively active Src (Y530F) (Figure 1b) . In untransfected cells, a trace amount of phosphorylated VE-cadherin could be detected but not in extracts of cells transfected by the empty vector or by Src-K298M. This is probably owing to a lower amount of VE-cadherin in the immunoprecipitated samples (Figure 1b , middle panel). These data indicate that active Src kinase induces VE-cadherin tyrosine phosphorylation in a heterologous cell system. Direct phosphorylation of the human VE-cadherin cytoplasmic domain by Src kinase To know whether VE-cadherin was directly phosphorylated by Src, we performed an in vitro kinase assay. We produced the human recombinant VE-cadherin cytoplasmic domain by in vitro translation. The first nine amino acids, containing a highly basic domain (and no tyrosine), were omitted to allow a correct level of expression in this system. A His-tag was included at the N-terminus to identify the recombinant protein with anti-His antibodies (Figure 2a, left panel) . A kinase assay was performed in the absence or in the presence of active Src and the reaction products were analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting with the anti-P-tyr antibody. The tyrosine-phosphorylated form of the VEcadherin cytoplasmic domain was detected after incubation with purified Src, whereas no signal was detected in the absence of the kinase (Figure 2a, right panel) . In addition, incubations with increasing concentrations of Src kinase units showed a dose-dependent phosphorylation of the VE-cadherin cytoplasmic fragment (Figure 2b ). Altogether, these results demonstrate that the recombinant VE-cadherin cytoplasmic domain is a direct substrate for Src kinase.
Phosphorylation of synthetic peptides containing each tyrosine of VE-cadherin cytoplasmic domain We wished to determine which of the tyrosine residues could serve as potential phosphorylation sites (Figure 3a ), thus we designed synthetic peptides representing every of all the nine possible tyrosine phosphorylation sites (Figure 3b ). Although it is highly unlikely that all of these tyrosine residues are phosphorylated in response to VEGF stimulation, these peptides were used as a starting point to reveal the sites The VE-cadherin cytoplasmic domain was incubated with increasing concentrations of purified Src (0.024-1.5 U); phosphorylation levels were revealed with anti-P-Tyr antibodies (top) and signals were quantified by densitometry (below).
VE-cadherin Tyr 685: a target site for Src kinase Y Wallez et al that could potentially be phosphorylation targets. All the synthetic peptides were subjected to an in vitro kinase assay with purified Src and [g-32 P]ATP. The reaction products were analysed by electrophoresis and autoradiography. Interestingly, as shown in Figure 3c , only the peptide comprising tyrosine residue 685 (Tyr685) (Y685) was strongly phosphorylated by Src. A kinetic study of the rate of phosphorylation was performed and showed that peptide phosphorylation was rapidly detected after 1 min incubation, which is 3 and 4) or the Tyr 645-peptide (lanes 5 and 6). Peptide concentration was either 1 mg (lanes 3 and 5) or 50 mg (lanes 4 and 6). VE-cadherin cytoplasmic domain was omitted in lane 1. Reaction products were analysed by immunoblotting with the anti-P-Tyr antibody.
VE-cadherin Tyr 685: a target site for Src kinase Y Wallez et al increased linearly up to 10 min and reached a plateau between 15 and 30 min (Figure 3d and e). A doseresponse phosphorylation reaction showed that peptide phosphorylation was already detected with 0.5 mg of peptide ( Figure 3f ). A competition experiment was performed between the VE-cadherin cytoplasmic domain and the peptide comprising the Y685. Samples were analysed by electrophoresis and analysed by immunoblotting with anti-P-tyrosine antibody. As illustrated in Figure 3g , the peptide comprising the Tyr685 efficiently competed with the VE-cadherin cytoplasmic domain for its phosphorylation. In contrast, the peptide comprising the Y645, which was not a target for Src, did not compete with the VE-cadherin cytoplasmic domain.
Altogether, these results show that, among the nine tyrosine residues of VE-cadherin cytoplasmic domain, Y685 is a highly specific target for Src in vitro.
Identification of VE-cadherin Y685 as phosphorylation target site in VEGF-activated HUVECs To expand the data obtained with the peptides, we wished to determine which of the cytoplasmic tyrosine residues could serve as potential phosphorylation sites in HUVECs in response to VEGF. Therefore, we performed a phosphopeptide map analysis after VEcadherin immunoprecipitation from VEGF-activated HUVECs. 32 P-labeled HUVECs were stimulated by VEGF (50 ng/ml) for 30 min in the presence or absence of SU6656, a specific inhibitor of Src kinase activity. Stimulation of HUVECs with VEGF resulted in strong induction of VE-cadherin phosphorylation, as estimated by autoradiography (Figure 4a ). This induction was abolished by SU6656. Correct molecular mass of the labeled bands was attested by co-migration of HUVEC extracts and revelation with anti-VE-cadherin antibodies (Figure 4a) .
The radioactive bands corresponding to VE-cadherin were excised from the gel and submitted to proteolysis with trypsin. Trypsin-digested VE-cadherin peptides were separated by electrophoresis according to the charge/mass ratio (x axis) and by liquid chromatography according to hydrophobicity (y axis), creating a phosphopeptide map. In this analysis, a corresponding increase in phosphorylation was detected in a unique trypsin-generated peptide from phosphorylated VEcadherin in VEGF-treated cells (Figure 4b) . Densitometric analysis of the phospho-peptide showed an increase in its level of phosphorylation upon VEGF stimulation, whereas it was strongly decreased by SU6656 treatment of the cells (Figure 4c ).
Position of phosphorylated residues. The peptide giving a reproducible spot in the phosphopeptide maps was extracted, hydrolysed in hydrochloric acid and separated by two-dimensional electrophoresis on thin-layer plates. The phosphorylated peptide (circled in Figure 4b ) was subjected to Edman degradation. The material in each cycle was spotted individually on thinlayer chromatography plates and the 32 P content in each fraction was quantified after exposure and detection using a BioImager. The positions of the radioactive peaks were the basis for tentative identification of a tryptic peptide containing a tyrosine residue in the corresponding position. Numbers of consecutive cycles in the Edman degradation and tentative alignment of tyrosine residues in tryptic VE-cadherin peptide with the radioactive peaks are indicated in (Figure 4d, left panel) . Amino-acid analysis of the radioactive peak showed that it contained a tyrosine residue (Figure 4d , right panel). Thus, it was concluded that the Y685 was the only phosphorylated tyrosine in VE-cadherin after HUVECs activation with VEGF.
Identification of VE-cadherin phosphorylation site in transfected CHO cells To confirm that Y685 phosphorylation in a cell system was Src-dependent, we performed the same experiment as above with CHO cells transfected with both VEcadherin and either active Src (Y530F) or kinase-dead Src (K298M). VE-cadherin immunoprecipitates from 32 P-labeled CHO cells transfected with constitutively active Src showed a much stronger radioactive signal than those transfected with kinase-dead Src, thereby confirming that active Src induced VE-cadherin phosphorylation (Figure 5a and b) . The phosphopeptide map of CHO-derived VE-cadherin was essentially indistinguishable from that of the endogenous protein in VEGF-activated HUVECs (Figure 5c ). Edman degradation of the radioactive peptide led to identify the Y685 as the only phosphosite in VE-cadherin in active Srctransfected CHO cells. Furthermore, we performed pull-down experiments with the SH2 domain of Csk, which is known to bind to the phosphorylated Y685 of VE-cadherin (Baumeister et al., 2005) . Lysates from VE-cadherin-transfected CHO cells, transfected either with active Src (Y530F) or the empty vector, were incubated with glutathione-Stransferase (GST) alone or GST fused to the Csk-SH2 domain pre-incubated with glutathione-sepharose beads. Proteins were separated by SDS-PAGE and immunoblotted with the anti-VE-cadherin antibody. No binding was observed with recombinant GST alone. Importantly, VE-cadherin binding to Csk-SH2 domain was highly enhanced in active Src-transfected CHO cells ( Figure 5d ). As Csk specifically binds to VE-cadherin phospho-Y685, our data further confirm that Y685 is the Src target site in VE-cadherin cytoplasmic domain.
Altogether, these results demonstrate that, in transfected CHO cells, Src-induced VE-cadherin phospho rylation on the same tyrosine as that phosphorylated in VEGF-activated HUVECs.
Inhibition of VE-cadherin tyrosine phosphorylation reduces VEGF-induced HUVECs migration
As SU6656 inhibits Tyr685 phosphorylation of VEcadherin, we thus examined the effects of SU6656 and PP2 on the VEGF-enhanced endothelial cells migration, a critical step in the process of angiogenesis. When confluent and quiescent monolayers of HUVECs were VE-cadherin Tyr 685: a target site for Src kinase Y Wallez et al wounded, recovery of these monolayers stimulated by VEGF initially depends on migration only, because proliferation of endothelial cells in response to wounding does not start before 24 h (Lauder et al., 1998) . HUVECs were grown on fibronectin-coated dishes and were subsequently scraped to create a wound. The dishes were observed at the time of wounding and every 3 h and up to 12 h of culture in the presence of VEGF (50 ng/ml). Phase-contrast micrographs are presented in Figure 6 . As shown in Figure 6a , repair of endothelial (Figure 6c ), the VEGF-induced repair of HUVEC monolayers was impaired and this effect was dependent on increasing concentrations of Src kinase inhibitors. These data indicate that pharmacological inhibition of Src kinase alters VEGF-induced endothelial cell migration in correlation with VE-cadherin tyrosine phosphorylation.
DISCUSSION
Tyrosine phosphorylation of VE-cadherin has been described in cells stimulated by several agents such as VEGF, thrombin, histamine, PAF and it was correlated with a rapid dissociation of adherens junctions, a critical step in angiogenesis and in inflammatory processes Zhao and Davis, 1998; Calcerrada et al., 2002; Shasby et al., 2002; Hudry-Clergeon et al., 2005) . Yet, the specific tyrosine kinases involved in this process and the target sites of phosphorylation were still elusive. In this report, we present evidences showing that VE-cadherin is a direct substrate for Src kinase in VEGF signaling pathway and that Y685 is a unique phosphorylated site in VE-cadherin cytoplasmic domain.
VE-cadherin cytoplasmic domain is phosphorylated by Src on Tyr685
The involvement of Src tyrosine kinase in VEGFinduced angiogenesis has been demonstrated by using dominant-negative Src or the tyrosine kinase Csk to block VEGF-induced blood vessel formation in mice (Eliceiri et al., 1999) . This suggests that Src kinase functions as a component of the VEGF-receptor signaling pathway. Previous studies of our laboratory showed that Src and VE-cadherin were constantly associated in HUVECs as well as in mouse tissues. Our present study showed that the VE-cadherin cytoplasmic domain is tyrosine phosphorylated by purified Src kinase in an in vitro kinase assay, in a timeand dose-dependent manner. These data support the notion that Src could directly phosphorylate VEcadherin in vivo. How Src interacts with VE-cadherin is unknown; however, it is important to note that a PXXP sequence is present in the cytoplasmic domain of VE-cadherin (   673   PPRP   676 ) that could well support association of VE-cadherin to the SH3 domain of Src (Boggon and Eck, 2004) and could constitute the basis for the observed physical and functional links between Src and VE-cadherin.
We demonstrated that Y685 (LY 685 AQV) was the unique target site for Src kinase in human VE-cadherin by four means: (i) in vitro, using a synthetic peptide approach, (ii) by VE-cadherin peptide mapping from HUVECs stimulated by VEGF, (iii) in VE-cadherin CHO cells co-transfected with active Src and (iv) by probing the phospho-VE-cadherin with the Csk-SH2 domain. Interestingly, the LY 685 AQV sequence fits the YxxV/I/L motif, which is a consensus site for phosphorylation by Src kinases (Lindquist et al., 2003) . Altogether, these data suggest that, in VEGF signaling GST or GST fused to Csk-SH2 domain (GST-CSK-SH2) were preabsorbed on gluthatione beads and incubated with extracts from VE-cadherin-CHO cells transfected either with active Src (SrcY530F) or the empty vector. Precipitates were analysed by SDS-PAGE and immunoblotted with the anti-VE-cadherin antibody. The arrow indicates the VE-cadherin band.
VE-cadherin
pathway, VE-cadherin-Y685 phosphorylation by Src may represent an important mechanism of regulation of VE-cadherin biological functions.
The covalent modification of the specific tyrosyl residues in growth factor receptors and in signaling molecules is involved in cellular communication (Pawson, 2004) . A conserved domain of about 100 amino acids, the SH2 domain, specifically recognizes and binds to phosphotyrosine, thereby promoting interactions of activated receptors and signaling molecules together (Pawson, 2004) . Indeed, Baumeister et al. (2005) reported that, upon VE-cadherin phosphorylation, the SH2 domain of Csk binds to phosphorylated Y685 of VE-cadherin, in yeast and in CHO cells (Baumeister et al., 2005) . These data are in agreement with our own findings showing that Y685 is phosphorylated upon VEGF stimulation. In addition, we demonstrated that Csk-SH2 domain binding to VE-cadherin was highly enhanced in active Src-transfected CHO cells. Therefore, we concluded that the recruitment of Csk by VE-cadherin was induced by Src. As Csk is a negative regulator of Src activity, its recruitment to VE-cadherin might represent an efficient process to regulate VE-cadherin tyrosine phosphorylation level. More recently, Potter et al. (2005) reported that either active Src or phosphatases inactivation may lead to VEcadherin phosphorylation on Y658 and Y731, but not Y685, which appears inconsistent with our own data (Potter et al., 2005) . However, in this case, VE-cadherin phosphorylation was not the result of VEGF stimulation; it is thus possible that other tyrosines than Y685 are phosphorylated in different cell culture conditions. None of these two previous studies clearly established that VE-cadherin was a direct substrate of Src. Our study provides evidence for a direct involvement of Src in VE-cadherin tyrosine phosphorylation on Y685 in response to VEGF. Thus we conclude that the early VEcadherin-related response in the VEGFR2 activation cascade is mediated by Src kinase.
VE-and N-cadherins share high homology in their cytoplasmic domains. N-cadherin is also tyrosine phosphorylated by Src on Y851 and Y883, which correspond to VE-cadherin tyrosine residues (Y725 and Y757, respectively) that are not phosphorylated. Interestingly, VE-cadherin Y685 has no homology with other tyrosines in the N-cadherin sequence. Thus, although VE-and N-cadherin cytoplasmic sequences are highly homologous, our data suggest that their regulation mechanisms might be different.
Inhibition of endothelial cell migration by Src blockers
One of the functional assays used to evaluate cadherin adhesive activity is the in vitro wound-healing test (Lampugnani, 1999) . In such test, increased cadherin adhesive activity at intercellular contacts is correlated with reduced healing, which is consistent with the role of cadherins in the inhibition of cell detachment. The addition of VEGF on HUVECs increased the rate of monolayer recovery, in agreement with the role of VEGF in endothelial junction disruption. In this assay, we showed that Src inhibitors prevented VEGF-induced healing, indicating that one of the effect of VEGF on endothelial cells, namely the decrease in adhesive homotypic activity, is mediated by Src. A salient finding of the present paper is that VEGF-induced VEcadherin-Y685 phosphorylation is blocked by the specific Src kinase inhibitor SU6656. These results suggest that phosphorylation of Y685 in VE-cadherin in response to VEGF may be a key player in the intracellular signaling involved in migration process of endothelial cells. Although we do not exclude the possibility that the inhibition of Src might have other effects independently of the inhibition of VE-cadherin Y685 phosphorylation (i.e., inhibition of VEGFinduced FAK phosphorylation) (Abu-Ghazaleh et al., 2001) , the fact that VE-cadherin is the major adhesive protein of adherens junctions in endothelial cells supports the argument that VEGF-induced VE-cadherin phosphorylation mediated via Src contributes to the inhibition of adhesive properties of endothelial cells.
Conclusions
VE-cadherin plays a key role in endothelial permeability and inflammation, and thus it is implicated in numerous physiological or pathological situations including angiogenesis. As endothelial cell invasion is a central process in angiogenesis and as angiogenesis is required for tumor growth, the inhibition of VE-cadherin phosphorylation on Y685 may represent a relevant therapeutic target in cancer and in inflammatory diseases.
Materials and methods
Antibodies
We used the following commercially available antibodies: for immunoprecipitation, the antibody against the human intracellular domain of VE-cadherin (C-19, Santa Cruz Biotechnology, Santa Cruz, CA, USA), and for immunoblotting, the mouse monoclonal antibody to human VE-cadherin (clone BV9) (Corada et al., 2001) or the C-19 antibody, and the monoclonal anti-phosphotyrosine (P-Tyr) antibody (clone 4G10) (Euromedex, Mundolsheim, France). As secondary antibodies, the horseradish peroxidase-conjugated goat antimouse and anti-goat immonoglobulin G antibodies (Bio-Rad Laboratories, Marnes la Coquette, France).
Reagents
Recombinant human VEGF 165 was from PeproTech Inc (Rocky Hill, NJ, USA). Purified Src was from UBI (Lake Placid, NY, USA) and [g 32 P]ATP (4500 Ci/mmol) from PerkinElmer (Boston, MA, USA). For cell labeling, orthophosphate was from GE Healthcare-Amersham Biosciences (Uppsala, Sweden).
In vitro Src kinase assay For phosphorylation assay, peptides were diluted in the reaction mixture (20 mM N-2-hydroxyl piperazine-N 0 -2-ethane sulfonic acid (pH 7.4), 10 mM MgCl 2 , 2 mM MnCl 2 , 1 mM dithiothreitol and 5 mM ATP plus 0.5 mCi of [g 32 P]ATP. The peptides used in this study were synthesized by Eurogentec (Seraing, Belgium). Phosphorylation reaction was initiated by the addition of constitutively active Src. After 20 min of incubation at 221C, the reaction was stopped by the addition of Laemmli buffer. Every experimental condition was performed in triplicate, and experiments were repeated three times. In all experiments, phosphorylated peptides were separated by an SDS-PAGE. Gels were dried and exposed by phosphorimaging.
Phosphorylated VE-cadherin from 32 P-labeled cells was analysed by two-dimensional phosphopeptide mapping and labeled cells were analysed by tryptic phosphopeptide mapping as described previously (Souchelnytskyi et al., 1996) .
Cell culture and transfection HUVECs were prepared as described by Lambeng et al. (2005) CHO-expressing human VE-cadherin were described previously and grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. For transient transfection of Src, 15 Â 10 6 CHO cells were transfected with appropriate plasmids by electroporation, then plated in 100-mm tissue culture dishes and grown for 48 h. The plasmids pcDNA3-Src-Y530F (constitutively active) and pcDNA3-Src-K298M (kinase-dead) were generous gifts from Michael Burbridge and Nicolas Cauquil from Servier (France).
Expression of recombinant VE-cadherin cytoplasmic domain
In vitro translation of the entire VE-cadherin cytoplasmic domain (R621-Y784) failed, whereas expression of a truncated version (A630-Y784) was successful. The corresponding DNA sequence was polymerase chain reaction (PCR) amplified from the human VE-cadherin cDNA using a forward primer, 5 0 -CTAGGATCCGCGCACGGCAA GAGCGTG-3 0 , and a reverse primer, 5 0 -TAAAGCTTAATA CAGCAGCTCCTCCCG-3 0 . The PCR fragment was digested by BamHI and HindIII and inserted into pQE30 (Qiagen, Courtaboeuf, France) in-frame with an N-terminus His-tag. The recombinant cDNA was then inserted into pET21b (Novagen, Darmstadt, Germany). The VE-cadherin cytoplasmic domain was produced by in vitro translation using the Proteo rapid Strep-Tag in vitro transcription/translation system from (IBA, Go¨ttingen, Germany), according to the manufacturer's protocol. Resulting products were analysed by immunoblotting with anti-His-tag antibodies.
Preparation of cell extracts, immunoprecipitation, electrophoresis and immunoblotting Cell lysates, immunoprecipitates and immunoblots were prepared and analysed as described previously by Lambeng et al. (2005) .
Pull-down experiments GST-Csk-SH2 DNA construct was a generous gift from Paul Slyke and Daniel Dumont (Toronto, Canada). All inductions yielded proteins of the expected size as judged by Coomassie staining. Quantification of GST constructs was accomplished via SDS-PAGE analysis. Pull-down experiments were carried out using GST fusion proteins that had been adsorbed onto the glutathione-Sepharose 4B matrix. Lysates from VEcadherin-transfected CHO cells transfected with either active Src (Y530F) or the empty vector were incubated at 41C overnight with GST alone or GST-Csk-SH2 with continuous stirring. The Sepharose beads were washed three times and centrifuged at 5000 r.p.m. for 30-60 s at 41C. Bound proteins were eluted by boiling in Laemmli buffer 5 min before 10% SDS-PAGE. After SDS-PAGE, the gels were subjected to Western blot analysis with VE-cadherin antibodies.
Migration assay (in vitro wounding)
In vitro scratch wounds were created by scraping the HUVECs monolayers with a sterile disposable cell scraper. After injury of the monolayer, the cells were gently washed and stimulated by VEGF alone or in combination with PP2 or SU6656. Endothelial cells migration from the edge of the wounded monolayer was examined after 12 h of VEGF stimulation after injury.
Abbreviations CHO, Chinese hamster ovary cells; HUVECs, human umbilical vein endothelial cells; VEGF, vascular endothelial growth factor; VEGFR-2, vascular endothelial growth factor receptor 2; VE-cadherin, vascular endothelial-cadherin; SDS, sodium dodecyl sulfate; SDS-PAGE, SDS-polyacrylamide gel electrophoresis.
